A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

Inclusion Criteria:

• For low-risk participant arms 9-11 only: Are greater than or equal to (≥)18 and lessthan (<)65 years of age at the time of randomization and do not have the risk factorsdefined in the bullet point directly below
• For high-risk participant arms 12 and 13 only: -- Are ≥18 years of age and satisfy at least one of the following risk factors at thetime of screening
• Are ≥65 years of age
• Have a body mass index (BMI) ≥ 35
• Have chronic kidney disease
• Have type 1 or type 2 diabetes
• Have immunosuppressive disease
• Are currently receiving immunosuppressive treatment, or
• Are ≥55 years of age AND have
• cardiovascular disease, OR
• hypertension, OR
• chronic obstructive pulmonary disease or other chronic respiratory disease
• For high-risk participant arms 12 and 13 only:
• Are 12-17 years of age (inclusive) AND satisfy at least one of the following riskfactors at the time of screening
• Have a BMI ≥85th percentile for their age and gender based on CDC growthcharts, https://www.cdc.gov/growthcharts/clinical_charts.htm
• Have sickle cell disease
• Have congenital or acquired heart disease
• Have neurodevelopmental disorders, for example, cerebral palsy
• Have a medical-related technological dependence, for example, tracheostomy,gastrostomy, or positive pressure ventilation (not related to COVID-19)
• Have asthma or reactive airway or other chronic respiratory disease thatrequires daily medication for control
• Have type 1 or type 2 diabetes
• Have chronic kidney disease
• Have immunosuppressive disease, or
• Are currently receiving immunosuppressive treatment. For high-risk participants arm 14 only:
• Are ≥12 years of age and satisfy at least one of the following risk factors at thetime of screening Are ≥65 years of age
• Are adults (≥18 years of age) with BMI >25 kg/m2 , or if age 12-17, have BMI ≥85thpercentile for their age and gender based on CDC growth charts
• Have chronic kidney disease
• Have type 1 or type 2 diabetes
• Have immunosuppressive disease
• Are currently receiving immunosuppressive treatment
• Have cardiovascular disease (including congenital heart disease) or hypertension
• Have chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonaryhypertension)
• Have sickle cell disease
• Have neurodevelopmental disorder (for example, cerebral palsy) or other conditionsthat confer medical complexity (for example, genetic or metabolic syndromes and severecongenital anomalies)
• Have a medical-related technological dependence (for example, tracheostomy,gastrostomy, or positive pressure ventilation [not related to COVID-19]
• Are currently not hospitalized
• Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat,malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath withexertion, nasal congestion or runny nose, new loss of smell, chills
• Must have sample taken for test confirming viral infection no more than 3 days priorto starting the drug infusion
• Are men or non-pregnant women who agree to contraceptive requirements
• Understand and agree to comply with planned study procedures
• Agree to the collection of nasopharyngeal swabs and venous blood
• The participant or legally authorized representative give signed informed consentand/or assent

Exclusion Criteria:

• For low-risk participants only: BMI ≥35
• Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air atsea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters ofmercury) to fractional inspired oxygen (FiO2) <300, respiratory rate ≥30 per minute,heart rate ≥125 per minute
• Require mechanical ventilation or anticipated impending need for mechanicalventilation
• Have known allergies to any of the components used in the formulation of theinterventions
• Have hemodynamic instability requiring use of pressors within 24 hours ofrandomization
• Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a riskwhen taking intervention
• Have any co-morbidity requiring surgery within <7 days, or that is consideredlife-threatening within 29 days
• Have any serious concomitant systemic disease, condition or disorder that, in theopinion of the investigator, should preclude participation in this study
• Have a history of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test prior to the one serving as eligibility for this study
• Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30days before dosing
• Have received treatment with a SARS-CoV-2 specific monoclonal antibody
• Have a history of convalescent COVID-19 plasma treatment
• For low-risk arms only: have received a SARS-CoV-2 vaccine or have participated in aprevious SARS-CoV-2 vaccine study and are currently blinded to treatment allotment
• Have participated, within the last 30 days, in a clinical study involving aninvestigational intervention. If the previous investigational intervention has a longhalf-life, 5 half-lives or 30 days, whichever is longer, should have passed
• Are concurrently enrolled in any other type of medical research judged not to bescientifically or medically compatible with this study
• Are pregnant or breast feeding
• Are investigator site personnel directly affiliated with this study
• Have body weight <40 kilograms